Anthera Pharma (ANTH) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. NVDA
2. PCVX
3. PTC
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to Anthera Pharma (ANTH) Misses Q2 EPS by 4c

Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results

August 9, 2016 8:35 AM EDT

Met enrollment target in SOLUTION study and enrolled first patient in SIMPLICITY study of SollpuraSuccessful sachet manufacturing to support SIMPLICITY study and commercial-scale lipase demonstration batchFirst patient enrolled in pivotal CHABLIS 7.5 clinical study of blisibimodPositive trends from analysis of BRIGHT-SC Phase 2 clinical study

HAYWARD, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today provided a business update and reported financial results for the second quarter ended June 30, 2016.

Recent Developments and Business Highlights:

Sollpura (liprotamase) Exocrine Pancreatic Insufficiency... More